Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Investors with a sufficient time horizon and understanding of China's reform efforts can find the investment opportunities rewarding, says Matthews China manager Richard Gao.